StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Shrikant Chouhan, Kotak Securities

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byShrikant Chouhan, Kotak SecuritiesHorizon: Swing (≤2wk)5 Nov 2026via NDTV Profit (Live)

Entry₹2,049Inferred
Target₹2,150
Total upside +4.93% (call closed)
Stop loss₹1,980-3.37% risk
Exit₹1,9805 Nov 2026, 9:20 am
Stop-loss hit-3.37%
Follow Shrikant Chouhan for new calls(32% target hit, 120 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 203 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 5 Nov 2026
7 supporting0 opposing
Supports the BUY call (7)

Dr. Lal PathLabs reported Q2 FY27 consolidated revenue of Rs 874 Cr, up 19.6% YoY, with PAT of Rs 194 Cr, up 27.5% YoY. The company also declared an interim dividend of Rs 5 per share.

NSE · Press Release·4 Nov · today

(opens in new tab)

Dr. Lal PathLabs reported Q2 FY27 consolidated revenue of Rs 874 Cr, up 19.6% YoY, with PAT increasing 27.5% to Rs 194 Cr. The company also declared an interim dividend of Rs 5 per share.

BSE · Company Update·4 Nov · today

(opens in new tab)

The company reported financial results for the quarter and half-year ended September 30, 2026, declared a second interim dividend of INR 5 per share, and announced a further investment of INR 49.5 cro

BSE · Company Update·4 Nov · today

(opens in new tab)

The company reported financial results for the quarter and half year ended September 30, 2026, and declared a second interim dividend of INR 5 per equity share.

NSE · Outcome of Board Meeting·4 Nov · today

(opens in new tab)

The company reported financial results for the quarter ended September 30, 2026, and declared a second interim dividend of INR 5 per equity share.

NSE · Outcome of Board Meeting·4 Nov · today

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Shrikant Chouhan, Kotak Securities

Every call and its outcome